Anidulafungin

阿尼芬净

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameAnidulafungin
Drug Alias Nameanidurafungin安多芬净anidulafunginaAnidulafunginumanidulafungine +[14] 
ClassificationSmall molecules > Heterocyclic drugs > AntibioticsSmall molecules > Heterocyclic drugs > Antifungals
Mechanisms of Action1,3-beta-glucan synthase inhibitors
Targets1,3-beta-glucan synthase
Therapy Area/IndicationsSolid tumoursNeutropeniaMyelodysplastic Syndromes +[16] 
Global Approved IndicationsCandidemiaCandidiasis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2006/02/17
Country/TerritoryCanadaUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesRaqualia Pharma IncPfizer IncPfizer Europe Ma Eeig +[5] 
Inactive CompaniesVicuron PharmaceuticalsRadboud University Medical CenterNational Cancer Institute +[4] 
Active IndicationsAbscessPeritonitisCandidemia +[5] 
Inactive IndicationsSolid tumoursNeutropeniaMyelodysplastic Syndromes +[11] 

Other Information

ATC CodeJ02AX06
Related LinksWikipediaDrugBankKEGG